Log In
Print
BCIQ
Print
Print this Print this
 

mericitabine (RG7128, RO5024048) (formerly R7128)

  Manage Alerts
Collapse Summary General Information
Company Gilead Sciences Inc.
DescriptionProdrug of PSI-6130, a cytidine nucleoside analog non-structural protein 5B (NS5B) polymerase inhibitor
Molecular Target HCV NS5B polymerase
Mechanism of ActionNucleoside analog polymerase inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat HCV genotype 1 infection in patients who failed previous therapy; Treat chronic HCV genotype 1 infection; Treat chronic hepatitis C virus (HCV) genotype 1 or 4 infection in treatment-naïve patients; Treat chronic hepatitis C virus (HCV) infection
Regulatory Designation

U.S. - Fast Track (Treat chronic hepatitis C virus (HCV) infection)

Partner

Chugai Pharmaceutical Co. Ltd.; Roche


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today